[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100468156":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":42,"collaborators":46,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":20,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetclax combined with Azacitidine","EXPERIMENTAL","T-cell acute lymphoblastic leukemia patients reveive venetoclax combined with azacitidine regimen treatment.",[13],"Drug: Venetoclax, Azacitidine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Venetoclax, Azacitidine","Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg\u002Fm2 subcutaneously once daily on days 1-7.",[9],null,[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"The First Affliated Hospital of Soochow University","RECRUITING","Suzhou","Jiangsu","215006","China","CN",{"type":31,"coordinates":32},"Point",[33,34],120.59538,31.30408,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":20,"email":41},"Sheng-Li Xue, M.D","CONTACT","(0086)51267781139","slxue@suda.edu.cn",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Sheng-Li Xue, MD","Professor",[47,49,51,53,55,57],{"name":48,"class":6},"Jining Medical University",{"name":50,"class":6},"The Second People's Hospital of Huai'an",{"name":52,"class":6},"The First Affiliated Hospital of Bengbu Medical University",{"name":54,"class":6},"Northern Jiangsu People's Hospital",{"name":56,"class":6},"Affiliated Hospital of Nantong University",{"name":58,"class":6},"Suzhou Hospital of Traditional Chinese Medicine","100468156","phase-2-study-of-venetoclax-combined-with-azacitidine-regimen-in-newly-diagnosed-t-all-patients-100468156",false,"NCT05376111","Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients","A Prospective, Multi-Center Study to Evaluate the Efficacy and Safety of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia Patients","Inclusion Criteria:\n\n1. Patients aged ≥ 15.\n2. Patients diagnosed with T-ALL according to 2016 WHO criteria for precursor lymphoid neoplasms.\n3. ECOG performance status score less than 3.\n4. Patients without serious heart, lung, liver, or kidney dysfunction.\n5. Ability to understand and voluntarily provide informed consent.\n\nExclusion Criteria:\n\n1. Patients who are allergic to the study drug or drugs with similar chemical structures.\n2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.\n3. Patients with uncontrolled active infection\n4. Patients with active bleeding.\n5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment.\n6. Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met.\n7. Liver dysfunction (total bilirubin \\> 1.5 times the upper limit of the normal range, ALT\u002FAST \\> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT\u002FAST \\> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \\> 1.5 times the upper limit of the normal value).\n8. Patients with a history of clinically significant QTc interval prolongation (male \\> 450 ms; female \\> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.\n9. Surgery on the main organs within the past six weeks.\n10. Drug abuse or long-term alcohol abuse that would affect the evaluation results.\n11. Patients who have received chemotherapy treatments related to the disease.","ALL","15 Years",{"count":69,"type":70},28,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.",[76,77],"T-cell Acute Lymphoblastic Leukemia","Recruiting",[79,80,81,82],"Venetoclax","Azacitidine","T-ALL","Newly diagnosed","2026-03-17",{"date":85,"type":86},"2026-03-19","ACTUAL",{"date":88,"type":86},"2022-04-01",{"date":90,"type":70},"2026-12-01",{"name":5,"class":6},1]